Comparative Pharmacology
Head-to-head clinical analysis: METHADONE MOUD versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADONE MOUD versus METHADOSE.
Methadone (MOUD) vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist with high affinity. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and maintenance effects.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Initial: 20-30 mg orally once daily, titrated to effect. Maintenance: 10-120 mg orally once daily. Route: oral (tablet, liquid). Frequency: once daily.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours following single dose; 13-50 hours with chronic dosing (due to tissue redistribution). Context: prolonged half-life supports once-daily dosing for opioid use disorder but requires careful titration to avoid accumulation.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Primarily renal (20-40% as unchanged drug, with urine pH-dependent elimination; 50% as metabolites including EDDP and EMDP). Biliary/fecal excretion accounts for approximately 10-15%.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category A/B
Category C
Opioid Agonist
Opioid Agonist